Details

Autor(en) / Beteiligte

• Avivi, Irit
• Perry, Chava
• Segman, Yafit
• Amit, Odelia
• Bar-On, Yaeli
• Katz, Ofrat Beyer
• Gold, Ronit
• Ribakovsky, Elena
• Avigdor, Abraham
• Vainstein, Vladimir
• Goldschmidt, Neta
• Ringelstein-Harlev, Shimrit
• Horowitz, Netanel A.
• Gutwein, Odit
• Gurion, Ronit
• Itchaki, Gilad
• Abadi, Uri
• Nemets, Anatoly
• Sofer, Orit
• Vezker, Miri
• Tadmor, Tamar
• Dally, Najib
• Filanovsky, Kalman
• Leiba, Merav
• Sarid, Nadav
• Benyamini, Noam
• Luttwak, Efrat
• Herishanu, Yair
• Ram, Ron

Titel

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Ist Teil von

• Annals of hematology, 2022-04, Vol.101 (4), p.755-762

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Polatuzumab (Pola)-based regimens and chimeric antigen receptor T (CAR T) cells provide superior outcome compared to conventional chemoimmunotherapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). Choosing between these strategies remains controversial. The efficacy of CAR T versus Pola-rituximab(R) /Pola-bendamustine(B)-R in R/R DLBCL patients after failing ≥2 lines of treatment was compared in a retrospective, ‘real-world’ study. Propensity score matching, for age, lymphoma category (de-novo/transformed), number of prior lines, Eastern Cooperative Oncology Group performance status and lactate dehydrogenase level, was applied to control for differences in patients’ characteristics. Response rate, progression-free survival (PFS) and overall survival (OS) were analyzed. A total of 82 patients, treated with CAR T ( n =41) or Pola-based regimens ( n =41), were included. No treatment-related deaths occurred with CAR T vs. 3 (7.3%) with Pola. The overall and complete response rates were 83% and 58% with CAR T vs. 66% and 44% with Pola-based-regimens ( p =0.077 and p =0.18, respectively). At a median follow-up of 9 months (range 1–19.2) and 16 months (range 0.7–25.3) for the CAR T and Pola arm respectively, the median PFS has not been reached for CAR T vs. 5.6 months for Pola (95% CI 3.6–7.6, p =0.014). Median OS has not been reached for CAR T vs. 10.8 months (95% CI 2.2–19.4) for Pola ( p =0.026). To conclude, in a real-world setting, treatment with CAR T achieved superior PFS and OS compared to Pola-based regimens in patients with R/R DLBCL.